Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07545512 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

ODSSEY-SCD_Identification Of Markers to preDict the rISk of Sudden Cardiac Death in Moderated LVEF in ischEmic cardiomyopathY

Study acronym: ODISSEY
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened Show 4 more changesShow less
    • Start date: Jul 1, 2026 to Oct 1, 2026
    • Trial sites expanded: 10 → 13 locations
    • Eligibility criteria expanded, about 11 words
    • Study description expanded, about 18 words
  2. Notable Start date: May 1, 2026 to Jul 1, 2026
    • Primary and study completion pushed from May 1, 2033 to Jul 1, 2033
    • Study sites: 8 to 10
    v6
  3. Minor Study sites: 6 to 8v5
  4. Minor Study sites: 5 to 6v4
  5. Minor Study sites: 3 to 5v3
  6. Minor Study sites: 2 to 3v2
  7. Minor Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Although advances in treatment and patient management have considerably improved post-infarction prognosis, the risk of sudden cardiac death remains a major concern. Sudden cardiac death (SCD) is defined as an unexpected death occurring within one hour of the onset of symptoms, often of arrhythmic origin. In patients who have survived a myocardial infarction, sudden death represents a persistent threat. This risk is often associated with complications such as left ventricular dysfunction, malignant ventricular arrhythmias, and structural alterations of the myocardium, all of which can favor the development of fatal cardiac events. Among the risk factors identified, reduced left ventricular ejection fraction, a history of ventricular arrhythmias and the presence of extensive scarring of the myocardium are particularly significant. Assessing the risk of SCD in post-infarction patients is crucial to determining appropriate prevention strategies, such as implanting automatic implantable defibrillators (ICDs). Assessment tools are varied, but currently only left ventricular ejection fraction (LVEF) \< 35% is identified and validated. However, this risk stratification is unsatisfactory, particularly in view of SCD in patients with a history of myocardial infarction and a moderately impaired LVEF (between 35 and 50%). Although the initial treatment of myocardial infarction is essential for the patient's immediate survival, managing the risk of sudden death in the long term remains a major clinical challenge. A multiparametric approach is needed to optimize prognosis and prevent premature death in these patients.
Trial Details
NCT Number NCT07545512
Lead Sponsor University Hospital, Clermont-Ferrand
Conditions
(from sponsor)
Myocardial Infarction (MI), Sudden Cardiac Death Due to Cardiac Arrhythmia
Related terms Myocardial Infarction
Enrollment 400 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov